Badrilla Ltd. is a biotechnology company founded in 2003 and located in Leeds, UK. Badrilla makes and distributes exceptional monoclonal and polyclonal antibodies to cardiovascular protein and phospho-protein targets. We source excellent antibodies from academic leaders and re-validate antibodies not made by ourselves in assays of relevance to our customers. Working with outstanding academic collaborators, we are developing new technologies to calibrate immunoassays, which will enable the performance of genuinely Quantitative Western blotting, Quantitative biomarker measurement, and Quantitative diagnostics. A patent covering the quantitative technology is granted in USA, Australia, Canada, China, Japan, and pending elsewhere.
Our aim is to provide products that work first time in the applications you deploy, which accelerate the progress of your research, and which satisfy your expectations in every way.
Paul J. England, Ph.D (Chairman): Appointed non-executive chairman in 2005. Prior to joining Badrilla, Paul was senior VP (Research) Aurora Biosciences, CA and Head Molecular Screening at SmithKline Beecham.
John Colyer, Ph.D. (Founder & CEO): Professor of Biotechnology at University of Leeds, and has founded companies Fluorescience Ltd (1998) and PhosphoProtein Research (1994). (Linkedin)
Gavin Allsop, Ph.D: Joined Badrilla in 2011 to manage the technical validation of new antibody products. (Linkedin)
Keith W. Dilly, PhD: (LinkedIn)